FDLI makes leadership appointment
This article was originally published in Scrip
The Food and Drug Law Institute (FDLI) has named former US FDA chief of staff Susan Winckler as the group's new president and CEO. She replaces James Kelley, who announced his departure in the summer. Ms Winckler is a pharmacist and attorney who served as FDA chief of staff from January 2007 to June 2009. She was most recently managing director of the medical products practice at Leavitt Partners, a consulting firm headed by former Health and Human Services secretary Mike Leavitt.
You may also be interested in...
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
Agency is working with manufacturers, including Takeda and Emergent BioSolutions, to accelerate development of hyperimmune globulin products, with an eye toward starting clinical testing in several months; new FDA guidelines on convalescent plasma collection for single-patient emergency IND use are helpful in understanding agency expectations around source plasma collection for manufactured products as well, Emergent SVP Laura Saward says.
Sanofi’s Lantus stands alone as the only insulin product still listed in the ‘Orange Book’ post-transition because it is referenced in Mylan/Biocon’s pending 505(b)(2) application for insulin glargine; the FDA said it stands ready to review biosimilar and interchangeable applications that reference the newly ‘deemed’ biologic products.